Submit efficacy data of Indian population: CDSCO Panel Tells Eli Lilly for approval of additional indications of Ixekizumab

Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) are both types of axial spondyloarthritis (axSpA), an inflammatory arthritis that affects the spine and joints

Ixekizumab is a biologic medication used to treat psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and nonradiographic axial spondyloarthritis. Biologic medications are proteins designed by humans that affect the immune system.

Ixekizumab is a humanized monoclonal antibody (IgG) that selectively binds to interleukin 17A (IL-17A); this prevents interleukin 17A from binding to the IL-17 receptor. Thus, this attenuates an inflammatory response mediated by interleukin 17A.

At the recent SEC meeting for analgesics and rheumatology held on October 3, 2024, the expert panel reviewed the proposal for the approval of additional indications, i.e., ankylosing spondylitis and non-radiographic axial spondyloarthritis of Ixekizumab solution for injection, 80 mg/ml in a prefilled auto-injector and prefilled syringe (r-DNA origin) with the request for a local clinical trial waiver.

After detailed deliberation, the committee noted that there is no efficacy data in Indian subjects.

In continuation, the expert panel opined the firm to submit efficacy data of the Indian population for the approval of proposed indications.

Also Read: Exemed Pharmaceuticals gets CDSCO Panel nod to study Sacubitril plus Valsartan film-coated sustained release tablet